Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Study Participants with Moderate to Severe Crohn's Disease
Summary description of the study
Crohn's disease (CD) is a gastrointestinal disorder that can cause chronic diarrhea with or without significant bleeding, abdominal pain, weight loss, and fever. This study examines the pharmacokinetics, efficacy, and safety of Risankizumab in children and adolescents aged 2 to < 18 years with moderate to severe active CD who are intolerant to other therapies or have responded inadequately. Risankizumab is an approved medication for adults with plaque psoriasis, psoriatic arthritis, and CD, and is being developed for the treatment of CD in pediatrics. This study consists of 3 cohorts that may participate in 3 sub-studies (SS). In cohort 1, patients aged 6 to under 18 years are enrolled. In cohort 2, patients aged 2 to under 6 years are enrolled. In cohort 3, patients aged 2 to under 18 years are enrolled. SS1 is an open-label induction phase where participants receive a weight-based induction therapy with Risankizumab. SS2 is a double-blind maintenance phase where participants are randomized to receive one of two doses of the weight-based induction therapy with Risankizumab. SS3 is an open continuation phase where participants receive Risankizumab based on their response in SS2. Approximately 110 children and adolescents with CD will be enrolled at approximately 100 study centers worldwide.
(BASEC)
Intervention under investigation
Participants in SS1 receive Risankizumab intravenously during the 12-week induction phase. Participants in SS2 receive Risankizumab subcutaneously during the 52-week randomized maintenance phase. Participants in SS3 receive Risankizumab subcutaneously during the 208-week open phase. Participants will be followed for approximately 140 days.
(BASEC)
Disease under investigation
Crohn's Disease
(BASEC)
– Children and adolescents aged 2 to < 18 years – Moderate to severe active CD, defined as a PCDAI score > 30, assessed at baseline – Endoscopic evidence of mucosal inflammation, documented by an SES CD of 6 for ileocolonic or colonic disease (or an SES CD of 4 for isolated ileal disease). – Documented intolerance or inadequate response to one or more of the following drug classes: aminosalicylates, oral locally acting corticosteroids, systemic steroids (prednisone or corresponding active ingredient), IMMs and/or biologics (BASEC)
Exclusion criteria
– Allergic reaction or significant sensitivity to any component of the investigational product (and excipients) and/or other drugs of the same class – Any of the following conditions: (a) Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD (b) CD diagnosis at age < 2 years (c) Diagnosis or suspicion of primary immunodeficiency (d) Currently known complications related to CD, including: -- Active abscess (abdominal or perianal) -- Symptomatic intestinal strictures -- > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigma, and left colon as well as rectum -- Fulminant colitis -- Toxic megacolon -- Or any other manifestations that may require surgical intervention during the study (e) Stoma or ileoanal pouch (f) Diagnosis of short bowel syndrome (g) Surgical intestinal resection within 3 months prior to baseline (except gastrointestinal surgeries that do not involve intestinal resection, such as appendectomy or stoma closure) or > 3 intestinal resections in the history (BASEC)
Trial sites
Bern, Zurich
(BASEC)
Sponsor
AbbVie Inc. North Chicago USA AbbVie AG Cham
(BASEC)
Contact
Contact Person Switzerland
AbbVie Medical Information
+41 41 399 16 89
medinfo.ch@clutterabbvie.comAbbVie AG
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Zurich
(BASEC)
Date of authorisation
13.02.2024
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab with Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) with Moderately to Severely Active Crohn's Disease (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available